



Granules India Limited

Regd. Off. :

2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081. INDIA

Ph : +91-40-30660000, 66760000 Fax : +91-40-23115145

E-mail : mail@granulesindia.com URL : www.granulesindia.com

CIN : L24110TG1991PLC012471

Date: 21st January 2016

To
National Stock Exchange of India Limited &
Bombay Stock Exchange Limited.
Scrip Code: NSE- GRANULES; BSE-532482.

Sub: Press Release-Reg.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,


Please find herewith a copy of Press Release issued by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For **GRANULES INDIA LIMITED**



CHAITANYA TUMMALA*
**(COMPANY SECRETARY &
COMPLIANCE OFFICER)**



Press Release

Granules USA, the wholly owned subsidiary of Granules India Ltd., entered into an agreement with Par Pharmaceutical Inc. to market generic version of omeprazole and sodium bicarbonate.

Hyderabad India – January 21 2016. Granules USA, the wholly owned subsidiary of Granules India Ltd., entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), to market the/a generic version of OTC omeprazole and sodium bicarbonate in North America following approval by the U.S. Food and Drug Administration's, which is currently expected in July 2016. Par Pharmaceutical's omeprazole and sodium bicarbonate is the generic equivalent of ©Merck/MSD Consumer Care, Inc's Zegerid® OTC.

Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the omeprazole from breaking down in stomach acid.

“Granules is excited that, through this exclusive agreement with Par Pharmaceutical, we can strengthen our OTC product basket and widen our offerings in the North American store brand market for meeting retailers' and consumers' desire for competitive market choices and alternatives.” said, Mr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Ltd.

“Continuing to reduce healthcare costs through our partnership with retailers, Granules is happy to offer consumers affordable medication choices,” remarked Robert Fisher, President of Consumer Health division of Granules USA.

Background on Granules

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Caution Statement:

Certain statements made above may be “forward looking statements” within the meaning of applicable laws and regulations.